If you’ve been researching semaglutide vs tirzepatide, you’re probably looking at two injectable medications that have completely reshaped how doctors think about obesity treatment. Both work. Both can produce weight loss that used to require bariatric surgery. But they aren’t identical, and the differences actually matter for real patients trying to choose.
The short version: tirzepatide tends to produce more weight loss on average, but semaglutide has a longer safety track record and is often easier to get covered. The longer version, which is what most patients actually need, depends on your starting weight, your other conditions, your tolerance for side effects, and your wallet.
Here’s what the data shows, what I see patients actually experience, and how to think about which one might fit your situation. For the foundational pharmacology, the NIH’s overview of GLP-1 receptor agonists is a solid place to start.
How Semaglutide vs Tirzepatide Actually Work
Semaglutide (sold as Wegovy for weight loss and Ozempic for type 2 diabetes) is a GLP-1 receptor agonist. It mimics a gut hormone that tells your brain you’re full, slows stomach emptying, and improves insulin response after meals.
Tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) is what’s called a dual agonist. It hits the same GLP-1 receptor that semaglutide does, plus a second receptor called GIP. That second pathway appears to amplify both the appetite suppression and the metabolic effects.
In practice, what I see most often is that patients on tirzepatide report feeling full faster and staying full longer than patients on semaglutide. Not always. But often enough that it shows up in the trial data too.
If you want a deeper background read on how this whole drug class quiets hunger signals, this patient guide to how GLP-1s work walks through it in plain language.
What the Trials Actually Show
The two big comparisons people quote:
- STEP trials (semaglutide 2.4 mg weekly): Average weight loss of about 14.9% of body weight at 68 weeks, per the 2021 NEJM publication.
- SURMOUNT-1 (tirzepatide 15 mg weekly): Average weight loss of about 20.9% at 72 weeks, per the 2022 NEJM publication.
There’s also SURMOUNT-5, a head-to-head trial published in 2025, that showed tirzepatide produced roughly 20.2% weight loss compared with about 13.7% for semaglutide over 72 weeks. That’s the cleanest direct comparison we have.
So on raw weight loss numbers, tirzepatide wins. But "wins" is doing a lot of work in that sentence. About 1 in 3 semaglutide patients in STEP hit 20% or greater weight loss too. Individual response varies more than the averages suggest.
Side Effects: More Similar Than Different
Both drugs share the same core side effect profile, mostly gastrointestinal:
- Nausea, especially in the first 4 to 8 weeks after each dose increase
- Constipation or diarrhea
- Burping, reflux, occasional vomiting
- Fatigue during the titration phase
- Rare but serious: pancreatitis, gallbladder issues, and a theoretical thyroid C-cell tumor risk (boxed warning on both)
In the SURMOUNT-5 head-to-head, the side effect rates were roughly comparable, though tirzepatide had slightly more GI complaints at the highest doses. Most patients tolerate either drug if the dose is escalated slowly. Rushing the titration is the single most common reason people quit.
If you’re weighing this against other options in the class, our breakdown of Wegovy vs Zepbound side effects, cost, and results gets into the brand-specific numbers.
Cost and Access in 2026
This is where the calculus gets messy.
Both drugs carry a list price north of $1,000 per month in the US without insurance. Coverage for obesity (as opposed to diabetes) remains spotty. Medicare still doesn’t routinely cover either for weight loss alone, though that’s been under active debate.
A few practical points:
- If you have type 2 diabetes, Ozempic or Mounjaro coverage is usually easier to secure than the weight-loss-labeled versions.
- Manufacturer savings programs from Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) can drop out-of-pocket costs significantly for commercially insured patients.
- Lilly’s self-pay vials for Zepbound have made tirzepatide somewhat more accessible than it was a year ago.
Compare current pricing on both medications at edrugstore.com before assuming one is out of reach. The gap between pharmacies can be surprising.
Which One Should You Ask About?
The honest answer is, it depends. But here’s how I’d frame the conversation with your prescriber.
Tirzepatide might be the better fit if:
- You have a higher BMI and need significant weight loss
- You’ve tried semaglutide and plateaued
- You also have type 2 diabetes or prediabetes
- Cost and coverage work out
Semaglutide might be the better fit if:
- You want the longer real-world safety record
- Insurance covers Wegovy but not Zepbound
- You’ve tolerated GLP-1s well before
- You’re starting from a lower BMI where the additional 5 to 6 percentage points of weight loss matter less
Some patients also want to know whether newer combination protocols change the picture. Our overview of GLP-1 vs GLP-1 Plus covers that.
A few caveats before you decide. Neither drug is a standalone solution. The trial results assumed reduced-calorie eating and increased activity alongside the medication. Stopping either drug typically leads to substantial weight regain, often 60 to 70% within a year, per follow-up data from the STEP-1 extension study. That’s a long-term commitment most patients don’t fully appreciate at the start.
The Bottom Line
When you compare semaglutide vs tirzepatide head-to-head, tirzepatide produces more weight loss on average, but semaglutide remains highly effective and often more accessible. Both come with real side effects, real cost considerations, and the same fundamental requirement: you need to stay on the medication, and you need to pair it with sustained lifestyle change.
Talk to your prescriber about which one fits your medical history, your weight goals, and your insurance situation. Ask specifically about titration speed, what to do if nausea becomes intolerable, and what the plan looks like once you reach your target weight. The choice between semaglutide vs tirzepatide isn’t one-size-fits-all, and the best drug is the one you can actually stay on.
This article is for informational purposes only and is not medical advice. Always consult a licensed pharmacist or physician before starting, stopping, or changing any medication.
References
- NIH Bookshelf: GLP-1 Receptor Agonists, pharmacology background on the drug class.
- NEJM, STEP-1 trial (semaglutide 2.4 mg), pivotal weight loss data for semaglutide.
- NEJM, SURMOUNT-1 trial (tirzepatide), pivotal weight loss data for tirzepatide.
- PubMed: STEP-1 extension follow-up, weight regain data after discontinuation.
Dr Steven Schlosser
Dr. Schlosser graduated from Lafayette College Phi Beta Kappa and attended Georgetown Medical School. He had 4 years of medical residency training at Tufts University in Boston in both Gynecology and Internal Medicine. He has had a spotless medical career for the past 40+ years and is Board Certified. Learn More